NeurologyLive® Friday 5 — June 12, 2026

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

Click the read more or watch now buttons for more details and information about each highlight.

1: Using Social Connection as “Medicine” in Parkinson Disease Care: Robert Cochrane, PhD

In a recent interview at the 2026 ATMRD Congress, Robert Cochrane, PhD, CEO and founder of Yes, And...eXercise (YAX), discussed how support groups, psychosocial connection, and hybrid telehealth models can complement pharmacologic treatment in Parkinson disease. [WATCH TIME: 3 minutes]

2: Masterclass at AMTRD Highlights Real-World Applications of Botulinum Toxin in Movement Disorders: Laxman Bahroo, MD

In a recent interview at the 2026 ATMRD Congress, Laxman Bahroo, MD, professor at MedStar Georgetown University Hospital, spoke about a live session that featured patient evaluations and injection demonstrations designed to help clinicians refine treatment strategies for dystonia, spasticity, sialorrhea, and other neurologic conditions. [WATCH TIME: 2 minutes]

3: Differentiating Pathologic Features of Alzheimer Disease and Lewy Body Dementia: Charbel Moussa, MBBS, PhD

In a recent interview at the 2026 ATMRD Congress, Charbel Moussa, MBBS, PhD, professor of neurology at Georgetown University Medical Center, discussed how clinicians can distinguish Alzheimer disease from Lewy body dementia. [WATCH TIME: 5 minutes]

4: Advances in Diagnosing Atypical Parkinsonisms and Ataxias: David Shprecher, DO, MSci, FAAN

In a recent Q&A at the 2026 ATMRD Congress, David Shprecher, DO, MSci, FAAN, director of Movement Disorders at Banner Sun Health Research Institute, discussed emerging biomarker and imaging technologies, the importance of clinical diagnostic expertise, and the evolving treatment landscape for atypical parkinsonian disorders and adult-onset ataxias.

5: Improving Recognition and Treatment of Hyperkinetic Movement Disorders: Zoltan Mari, MD

In a recent at the 2026 ATMRD Congress, Zoltan Mari, MD, director of the Parkinson's Disease and Movement Disorders Program at the Cleveland Clinic, discussed the importance of movement phenomenology and accurate diagnosis in guiding treatment decisions for patients with hyperkinetic disorders. [WATCH TIME: 7 minutes]

Don’t have time to read or watch a full video interview? Click here to check out our shorts!